Intensive therapy and autologous blood and marrow transplantation (ABMT) is an established post-remission treatment for acute myeloid leukemia (AML), although its exact role remains controversial and few data are available regarding longer-term outcomes. We examined the long-term outcome of patients with AML transplanted at a single center using uniform intensive therapy consisting of etoposide, melphalan and TBI. In all, 145 patients with AML underwent ABMT: 117 in first remission, 21 in second remission and seven beyond second remission. EFS and OS were significantly predicted by remission status (Po0.0001). For transplantation in first remission, 8 year EFS and OS were 55% (95% CI, 44-64%) and 62% (95% CI, 50-72%), respectively. By multivariate analysis, only age (P ¼ 0.04) and cytogenetic risk group (P ¼ 0.006) influenced OS. For patients transplanted in second remission, 8 year EFS and OS were 30% (95% CI, 9-55%) and 36% (95% CI, 13-60%), respectively. No pre-transplant variables significantly predicted outcome. None of the seven patients who underwent ABMT beyond second remission or in early relapse were long-term survivors. ABMT can provide long-term antileukemic control for patients with AML in first remission. For patients in second remission approximately 30% can achieve cure with ABMT, and this option may be preferable to alternate donor allogeneic stem cell transplantation.
The role of autologous blood or marrow transplantation (ABMT) in the management of acute myeloid leukemia (AML) remains controversial. Early studies established the feasibility and promise of this approach, [1] [2] [3] [4] [5] leading to the conduct of several randomized controlled trials examining the utility of ABMT to prevent relapse in patients with AML in first remission. [6] [7] [8] [9] These trials have yielded conflicting results on the overall benefit of ABMT, although relapse rates have been consistently reduced compared with the chemotherapy-only arms. This superior antileukemic advantage of ABMT is, however, offset by substantial early transplant-related mortality ranging 5-15%. [6] [7] [8] [9] There are also scant published data describing the long-term outcome of patients with AML undergoing ABMT in first remission.
There are less data and no randomized trials exploring the role of ABMT for patients with AML in second complete remission or beyond. Registry data have demonstrated that long-term survival is achievable after ABMT, 10 although establishing a durable remission and obtaining an adequate stem cell graft can be problematic for patients with relapsed AML. Conventional wisdom holds that matched-related allogeneic stem cell transplantation is the therapy of choice for younger patients with AML in second remission. For patients without a matched-related donor, it remains uncertain whether an ABMT or unrelated donor bone marrow transplant is preferable, 11 although a recent registry study suggested that ABMT resulted in superior overall survival. 12 In 1986, we began to study the application of high-dose therapy with ABMT for patients with AML in remission in the hope of reducing relapse and improving survival. We employed the intensive therapy regimen of etoposide, melphalan, and total body irradiation (TBI) because of high antileukemic activity of the individual agents and the acceptable toxicity documented in our initial studies. 13 In this paper, we present the long-term outcome of patients with AML transplanted with this approach at a single center.
Patients and methods

Patients
Between December 1986 and December 2001, consecutive patients with AML who underwent ABMT in the University of Toronto Autologous Blood and Marrow Transplant Program were identified. Throughout this period, patients with AML were eligible for ABMT if their leukemia was in complete remission and an human leukocyte antigen (HLA)-identical donor was not available.
After 1997, patients with good-risk cytogenetics (t(15;17), inv16, t(8;21)) were not offered ABMT in first remission. Cytogenetic analysis on bone marrow obtained prior to induction chemotherapy was performed using standard Gbanding of at least 20 metaphases. Cytogenetic risk groups were assigned according to MRC criteria.
14 Patient and disease characteristics and outcome data were abstracted from a prospectively acquired transplant database and patient medical records according to a protocol approved by the institution's research ethics board.
Progenitor cell collection and transplantation
The choice of induction and consolidation chemotherapy was at the discretion of the referring physician. Patients transplanted in first remission received at least one cycle of consolidation chemotherapy prior to stem cell collection, whereas patients referred in second remission generally proceeded to stem cell collection without further chemotherapy. During the initial years of the ABMT program an unpurged bone marrow graft was utilized. Marrow was collected in the outpatient setting under general anesthesia provided that bilateral bone marrow aspirates performed within 2 weeks of harvest demonstrated less than 5% blasts. The target minimum mononuclear cell dose was 2.0 Â 10 8 cells/kg. During later years, peripheral blood progenitor cells were collected with bone marrow used only in the event of failure to mobilize peripheral blood progenitors. Blood progenitor cells were mobilized with a variety of chemotherapy and cytokine protocols with a target minimum CD34 þ cell count of 2.0 Â 10 6 /kg. Patients in first remission all received high-dose therapy consisting of etoposide 60 mg/kg i.v. on day À4, melphalan 140 mg/m 2 i.v. on day À3 and TBI 500 cGy in a single midplane dose delivered at 50 cGy/min on day 0. Beyond first remission, patients received etoposide 60 mg/kg i.v. on day À4, melphalan 140 mg/m 2 i.v. on day À3 and fractionated TBI 200 cGy twice daily for six doses on day À2 to 0; four patients receiving busulfan/cyclophosphanide (BU/CY) conditioning are not included in this paper. Peripheral blood progenitor cells or marrow was infused on day 0. Routine transfusion triggers included platelets o20 Â 10 9 /l in the early study period and o10 Â 10 9 /l in the last 3 years, and hemoglobin o8 g/dl. (granulocyte colony-stimulating factor) G-CSF 300 mg was commenced on day 7 during the later study period.
Statistical analysis
Study end points were defined as follows: transplant-related mortality included deaths in ongoing complete remission; event-free survival was the time from transplant to first event (relapse, secondary MDS/AML or death); overall survival was the time from transplant to death from any cause; and relapse risk was the cumulative probability of relapse, censoring at death in complete remission. Variables analyzed included: patient characteristics (age, gender); disease characteristics at diagnosis (white cell count, cytogenetic risk group according to the MRC classification 14 ) ; disease characteristics at transplant (disease status at ABMT, number of inductions to achieve remission, number of post-remission chemotherapy cycles, time from achievement of remission to ABMT, and remission duration for relapsed patients); and transplant factors (stem cell source and dose). The probabilities of event-free and overall survival were calculated from the day of transplant according to the method of Kaplan and Meier. The cumulative risk of relapse with time was estimated using Kaplan-Meier survival approach censoring at death in complete remission. Variables affecting these end points were compared using the log rank test (categorical variables) or Cox proportional hazards (continuous variables). For multivariate analysis, a Cox proportional hazards model was constructed using a backward stepwise selection approach incorporating all variables with a P-value o0.25 in univariate analysis. Statistical analysis was performed using the STATA (University of Texas) statistics package. Summary statistics use median values with ranges in brackets.
Results
Patients
In all, 145 patients with AML underwent ABMT during the study period. At the time of blood cell collection, all patients had AML in complete remission. At the time of transplantation 117, 21, four and one were in first, second, third and fourth remission, respectively, and two were in early relapse. Patient characteristics according to remission status are detailed in Table 1 .
For the 117 patients in first remission, the median age at the time of ABMT was 43 years, 30% were older than 50 years and 5% older than 60 years. The median white cell count at diagnosis was 14 Â 10 9 /l and 6% had a white cell count 4100 Â 10 9 /l. In total, 15 patients had good-risk cytogenetics consisting of nine with t(15;17), three with t(8;21) and three with inv(16). In total, 68 patients were classified as intermediate-risk and nine as poor risk. Karyotype analysis either failed or was not available for 25 patients. The median time from achievement of remission to transplantation was 6 months with all except two patients proceeding to ABMT within 1 year.
Of the 21 patients transplanted in second remission, the median age at ABMT was 47 years, 10 were older than 50 years and four older than 60 years. Cytogenetic risk group was classified as good (n ¼ 4) consisting of three with t(15;17) and one with t(8;21), intermediate (n ¼ 7), poor (n ¼ 1) or unknown (n ¼ 9). The median duration of first remission was 13 months (range, 0.9-37 months).
Of the seven patients transplanted beyond second remission, the median age was 38 years (range, 26-57 years). Cytogenetic risk group was classified as good (n ¼ 2) with one t(8;21) and one inv (16) 
In all, 10 patients had antecedent disorders: six solid organ tumors treated with surgery alone (skin cancer n ¼ 3, cervical cancer n ¼ 2, colon cancer n ¼ 1); Hodgkin's disease treated with radiotherapy (n ¼ 1); Crohn's disease treated with azathioprine (n ¼ 1); and myelodysplastic syndrome with no prior therapy (n ¼ 2).
Marrow and peripheral blood progenitor cell collection
Details of the cell source and dose are given in Table 2 . The majority of patients received an unmanipulated bone marrow graft with a median nucleated cell dose of 2.2 Â 10 8 /kg for patients harvested in both first and second remission. There were no significant complications of the harvest procedure, the details of which have been reported previously. 15 In total, 26% percent of patients transplanted in first remission received only a peripheral blood progenitor cell graft with a median CD34 þ cell dose of 4.23 Â 10 6 /kg, whereas 7% of patients were infused with both a marrow and peripheral blood progenitor cell graft due to failure to collect adequate numbers of peripheral blood progenitors. Adequate numbers of peripheral blood progenitor cells were unable to be collected from patients beyond first remission, although the majority of these patients proceeded directly to bone marrow rather than peripheral blood harvesting.
The median time to neutrophil recovery to more than 0.5 Â 10 9 /l was 30 days (range, 11-400 þ days), 11 days (range, 6-16 days) and 25 days (range, 11-40 days) for patients receiving grafts of bone marrow, peripheral blood progenitor cells, or both products, respectively. The corresponding times for platelet engraftment greater than 20 Â 10 9 /l were 50 days (range, þ days), 12 days (range, 9-95 days) and 35 days (range, 11-109 days), respectively.
Outcome
As detailed in Table 3 and depicted in Figure 1 , overall and event-free survival were significantly influenced by remission status at the time of transplant (Po0.0001 for both). The long-term outcomes presented below are analyzed according to this remission status. Table 3 details the outcome of patients autografted in first remission. The median follow-up for survivors was 53 months (range, 1.3-176 months). Early (day 100) transplant-related mortality was 3.4%, rising to 6% at 1 year. The 8-year event-free and overall survivals were 55 and 62%, respectively. The cumulative risk of relapse at 8 years was 35%. In all, 36 patients have died due to relapse (n ¼ 25) or complications of ABMT (n ¼ 11) including secondary MDS/AML (n ¼ 4), sepsis (n ¼ 3), sudden cardiac death (n ¼ 1), pulmonary toxicity (n ¼ 1), disseminated varicella zoster virus infection (n ¼ 1) and unknown (n ¼ 1). Long-term outcomes of autotransplant for AML P Mollee et al By univariate analysis, worse event-free survival was predicted by older age (P ¼ 0.08), female sex (P ¼ 0.04), adverse cytogenetic risk (P ¼ 0.009), lower diagnostic white cell count (P ¼ 0.08) and needing more than one induction course to achieve remission (Po0.001). There was no impact of number of consolidation cycles prior to progenitor cell harvesting (1 vs 41 cycles) or stem cell source (peripheral blood vs bone marrow vs combined graft) on outcome. Figure 2 depicts the event-free survival for patients transplanted in first remission according to cytogenetic risk group. For the 15 good risk patients the 8-year event-free survival was 87%. Two of the nine patients with t(15;17) and none of the six patients with t(8;21) or inv(16) have relapsed. For the 67 patients with intermediate risk disease, the 8-year event-free survival was 47%, and this was not significantly different from those whose cytogenetic analysis failed or was unavailable. Of the nine patients with poor risk cytogenetics, the 8-year event-free survival was 44%, the four survivors including patients with -7, 5q-and t(3;5)(q23;q33). In multivariate analysis of those patients with available cytogenetic data, only age (P ¼ 0.05), cytogenetic risk group (P ¼ 0.03) and number of induction courses (P ¼ 0.02) influenced event-free survival (Table 4) . Table 5 lists the impact of pre-transplant factors on overall survival. Overall survival was influenced negatively in univariate analysis by older age (P ¼ 0.06), female sex (P ¼ 0.04), and worse cytogenetic risk group (P ¼ 0.002). The 8-year overall survivals according to cytogenetic risk were 93, 55 and 44% for good, intermediate and poor risk disease, respectively (Figure 2) . For the nine patients with t(15;17) the 8-year overall survival was 88%. In multivariate analysis of those patients with available cytogenetic data, only advancing age (P ¼ 0.02) and worse cytogenetic risk group (P ¼ 0.009) impacted unfavorably on overall survival (Table 5) .
Patients transplanted in first remission
No pre-transplant variable significantly influenced the cumulative risk of leukemia relapse, although there was a trend for a more favorable cytogenetic risk group to be associated with reduced relapse (P ¼ 0.09).
In a subgroup analysis of first remission patients who received only a bone marrow graft (n ¼ 79), a higher CFU-GM count predicted for worse overall survival (HR 1.06, 95% CI 1.01-1.11). This finding was duplicated when the CFU-GM count was analyzed as a categorical variable and persisted in multivariate analysis (HR 1.12, 95% CI 1.05-1.20). There was no association between overall survival and the marrow mononucleated cell count in those receiving a bone marrow graft or between overall survival and CD34 þ cell content in the cell product of those who received only peripheral blood progenitor cells (n ¼ 30).
Patients transplanted in second remission
The outcome of patients autografted in second remission is detailed in Table 3 and shown graphically in Figure 1 . The median follow-up for survivors was 32 months (range, 2.3-124 months). Early (day 100) transplant-related mortality was higher than patients autografted in first remission at 9.5%, rising to 14% at 1 year. In total, 13 patients have died due to relapse (n ¼ 7) or complications of ABMT (n ¼ 11) including secondary MDS/AML (n ¼ 1), sepsis (n ¼ 2), pulmonary toxicity (n ¼ 2) and unknown (n ¼ 1 
Patients transplanted beyond second remission
None of the seven patients transplanted in third or fourth remission or in early relapse were long-term survivors. In Long-term outcomes of autotransplant for AML P Mollee et al all, 29% of deaths were transplant-related with relapses occurring rapidly after transplant, leading to a median event-free survival of only 2.9 months and a median overall survival of 9 months.
Discussion
ABMT has been widely applied to the management of patients with AML, although controversy remains as to its exact role. Our data show that for patients with AML in first remission, melphalan, etoposide, TBI and ABMT result in a survival of 62% at 8 years. Furthermore, approximately one-third of patients autografted in second remission were long-term survivors. Several randomized trials have examined the issue of post-remission therapy for patients with AML in first remission. [6] [7] [8] [9] Generally, patients with a matched-related donor have been assigned to receive allotransplant, while those without a donor have been randomized to chemotherapy alone or chemotherapy followed by ABMT. The relative merits of these studies have been extensively debated [16] [17] [18] [19] and while ABMT may result in improved disease-free survival compared with chemotherapy alone, 6, 8 this has not translated into better overall survival. A consistent finding across these trials, however, has been a reduction in relapse rates in the ABMT arm compared with the chemotherapy arm, suggesting that ABMT is more efficacious at inducing a state of minimal residual disease. This benefit of reduced relapse is offset by increased therapy-related mortality after ABMT, ranging from 6.5 to 14% in the randomized trials. [6] [7] [8] [9] In cohort studies such as ours, patients who actually proceed to ABMT are a highly selected group in that they have maintained an adequate performance status and organ function through their induction and consolidation phases, and have not suffered from early disease recurrence. Our 8-year event-free and overall survivals of 55 and 62%, respectively, compare favorably to those reported among patients actually receiving an autograft in the randomized studies, where the event-free and overall survivals were approximately 45 and 55% at 4-7 years, respectively. Thus, reduced transplant-related mortality as demonstrated in our series could lead to improved survival and suggests that ABMT may still have a role in the consolidation of patients with AML in first remission. The achievement of a state of minimal residual disease following ABMT may also be an ideal platform for a variety of noncross-resistant strategies, including immunotherapeutic approaches, to eradicate residual leukemia. 20, 21 We identified age and cytogenetic risk as the most important determinants of overall survival after ABMT for AML in first remission, findings observed by others. 6, 7, [22] [23] [24] Of interest was the excellent outcome of the good-risk group with an 8-year overall survival of 93%, a group for whom allogeneic and autologous stem cell transplantation is normally withheld. The outcome of patients with poorrisk cytogenetics was also encouraging with a long-term survival of 44%. It can, of course, be argued that time censoring bias is responsible for these results. 25 The Royal Marsden group recently demonstrated that more than one course of consolidation chemotherapy prior to ABMT beneficially influenced outcome in those with a favorable karyotype. 23 As only two patients with good-risk cytogenetics received less than two consolidation cycles, we were unable to confirm this finding. Similar to their report, however, we found no additional benefit from delivering 41 cycle of consolidation to patients with other karyotypes over that achieved with one cycle of consolidation. We also found that among patients who were transplanted with bone marrow only, a higher CFU-GM count was associated with an adverse prognosis. A high bone marrow CFU-GM level may indicate less chemotherapy-related stem cell toxicity and thus, inadequate 'in vivo' purging of leukemia during induction and consolidation leading to a higher relapse rate. This is similar to the observations of Keating 26 and Feller, 27 who noted that high numbers of peripheral blood mobilized CD34 þ cells after the first consolidation course were associated with increased relapse and worse disease-free survival. In the setting of mafosfamide-purged bone marrow grafts, higher marrow doses pre-purging and lower marrow doses after purging have predicted for reduced relapse and better leukemia-free survival. 28 It seems that higher doses of residual CFU-GM reflect inadequate 'in vitro' purging of leukemia leading to an increased relapse rate, although the discrepant finding of higher pre-purging marrow dose and improved survival remains unexplained.
Younger patients with AML in second remission are generally managed with allogeneic transplantation as the treatment of choice, leading to event-free survival in the range of 30-40%. Many patients do not have a related donor and are thus candidates for either unrelated donor allogeneic transplantation or ABMT. It is perhaps Table 5 Variables associated with overall survival following autotransplantation for AML in CR1 Long-term outcomes of autotransplant for AML P Mollee et al under-appreciated that ABMT can cure relapsed AML (providing a second remission can be achieved and an adequate graft obtained). In our paper, approximately onethird of patients transplanted in second remission were alive at 8 years and 30% were disease-free. These data are consistent with other reports demonstrating the ability of ABMT to produce event-free survival in the range of 20-40% for these patients. 10, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Ringden initially reported a retrospective matched-pair analysis from the European Cooperative Group for Blood and Marrow Transplantation (EBMT) comparing unrelated donor transplantation and ABMT for AML in second remission, demonstrating similar 2 year survivals of 42 and 48%, respectively.
11 A recent larger comparative study from the NMDP, IBMTR and ABMTR concluded that ABMT resulted in significantly better overall survival compared to unrelated donor transplantation for patients with AML in second remission with adjusted 3 year survival of 46 vs 34%, respectively. 12 These data suggest that ABMT may be preferable to alternate donor allogeneic transplantation for this subgroup of patients.
In summary, high-dose therapy with etoposide, melphalan and TBI provides effective long-term antileukemic activity for patients with AML in first remission. While selection bias limits assessment of the utility of ABMT outside the setting of randomized trials, the low transplantrelated mortality in our series suggests that ABMT may play a role in the management of these patients, particularly in achieving a state of minimal residual disease. ABMT may thus provide a platform for therapeutic strategies to eradicate minimal residual disease. Approximately 30% of patients with AML in second remission can be cured with ABMT, and this option may be preferable to alternate donor allotransplantation for those without a matched related donor.
